RU2749376C1 - Новые полииминокетоальдегиды - Google Patents
Новые полииминокетоальдегиды Download PDFInfo
- Publication number
- RU2749376C1 RU2749376C1 RU2019126389A RU2019126389A RU2749376C1 RU 2749376 C1 RU2749376 C1 RU 2749376C1 RU 2019126389 A RU2019126389 A RU 2019126389A RU 2019126389 A RU2019126389 A RU 2019126389A RU 2749376 C1 RU2749376 C1 RU 2749376C1
- Authority
- RU
- Russia
- Prior art keywords
- compound
- general formula
- gram
- treatment
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010024229 Leprosy Diseases 0.000 claims description 4
- 206010024238 Leptospirosis Diseases 0.000 claims description 4
- 206010035148 Plague Diseases 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010018612 Gonorrhoea Diseases 0.000 claims description 3
- 208000037386 Typhoid Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000028104 epidemic louse-borne typhus Diseases 0.000 claims description 3
- 201000008297 typhoid fever Diseases 0.000 claims description 3
- 206010061393 typhus Diseases 0.000 claims description 3
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 206010006500 Brucellosis Diseases 0.000 claims description 2
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 claims description 2
- 206010051226 Campylobacter infection Diseases 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 208000004023 Legionellosis Diseases 0.000 claims description 2
- 206010024641 Listeriosis Diseases 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
- 206010029443 Nocardia Infections Diseases 0.000 claims description 2
- 206010029444 Nocardiosis Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 241000287531 Psittacidae Species 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 208000034784 Tularaemia Diseases 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 201000009904 bacterial meningitis Diseases 0.000 claims description 2
- 201000006824 bubonic plague Diseases 0.000 claims description 2
- 201000004927 campylobacteriosis Diseases 0.000 claims description 2
- 230000002920 convulsive effect Effects 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 208000001786 gonorrhea Diseases 0.000 claims description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 2
- 201000004015 melioidosis Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 206010044325 trachoma Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 206010037688 Q fever Diseases 0.000 claims 1
- 206010039438 Salmonella Infections Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 206010039447 salmonellosis Diseases 0.000 claims 1
- 208000006379 syphilis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 10
- -1 polyimino Polymers 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101100517202 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) NRPS1 gene Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- LGVJIYCMHMKTPB-DMTCNVIQSA-N (2s,3r)-2-azaniumyl-3-hydroxypentanoate Chemical compound CC[C@@H](O)[C@H](N)C(O)=O LGVJIYCMHMKTPB-DMTCNVIQSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710163092 D-lysergyl-peptide-synthetase subunit 1 Proteins 0.000 description 1
- JDMUPRLRUUMCTL-VIFPVBQESA-N D-pantetheine 4'-phosphate Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS JDMUPRLRUUMCTL-VIFPVBQESA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101710139121 Nonribosomal peptide synthetase 1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 108010043055 cyclosporin A synthetase Proteins 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- UILMMYFRNCCPLK-UHFFFAOYSA-N sulfuric acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound OS(O)(=O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 UILMMYFRNCCPLK-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960002712 trimethoprim sulfate Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
- C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HR2017/000002 WO2018154344A1 (en) | 2017-02-21 | 2017-02-21 | New polyimino ketoaldehydes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2749376C1 true RU2749376C1 (ru) | 2021-06-09 |
Family
ID=58530574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019126389A RU2749376C1 (ru) | 2017-02-21 | 2017-02-21 | Новые полииминокетоальдегиды |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11180444B2 (https=) |
| EP (1) | EP3598868B1 (https=) |
| JP (2) | JP2020508297A (https=) |
| KR (1) | KR102296053B1 (https=) |
| CN (1) | CN110325245A (https=) |
| AU (1) | AU2017399805B2 (https=) |
| CA (1) | CA3053236C (https=) |
| DK (1) | DK3598868T3 (https=) |
| ES (1) | ES2888948T3 (https=) |
| HR (1) | HRP20211412T1 (https=) |
| PL (1) | PL3598868T3 (https=) |
| PT (1) | PT3598868T (https=) |
| RU (1) | RU2749376C1 (https=) |
| SI (1) | SI3598868T1 (https=) |
| WO (1) | WO2018154344A1 (https=) |
| ZA (1) | ZA201905612B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154344A1 (en) * | 2017-02-21 | 2018-08-30 | Novum Spero Ltd. | New polyimino ketoaldehydes |
| EP3843877A4 (en) | 2018-08-27 | 2022-08-24 | Electric Power Research Institute, Inc. | ORGANIC METAL FRAMEWORKS FOR THE REMOVAL OF MULTIPLE LIQUID-PHASE COMPOUNDS AND METHODS OF USE AND PRODUCTION THEREOF |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2484085C2 (ru) * | 2007-03-06 | 2013-06-10 | Зика Текнолоджи Аг | Диальдимин, эмульсия, содержащая диальдимин, а также двухкомпонентная полиуретановая композиция и ее применение |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154344A1 (en) * | 2017-02-21 | 2018-08-30 | Novum Spero Ltd. | New polyimino ketoaldehydes |
-
2017
- 2017-02-21 WO PCT/HR2017/000002 patent/WO2018154344A1/en not_active Ceased
- 2017-02-21 CA CA3053236A patent/CA3053236C/en active Active
- 2017-02-21 AU AU2017399805A patent/AU2017399805B2/en active Active
- 2017-02-21 RU RU2019126389A patent/RU2749376C1/ru active
- 2017-02-21 CN CN201780087044.4A patent/CN110325245A/zh active Pending
- 2017-02-21 DK DK17716587.5T patent/DK3598868T3/da active
- 2017-02-21 PT PT177165875T patent/PT3598868T/pt unknown
- 2017-02-21 KR KR1020197026606A patent/KR102296053B1/ko active Active
- 2017-02-21 EP EP17716587.5A patent/EP3598868B1/en active Active
- 2017-02-21 JP JP2019543913A patent/JP2020508297A/ja active Pending
- 2017-02-21 PL PL17716587T patent/PL3598868T3/pl unknown
- 2017-02-21 ES ES17716587T patent/ES2888948T3/es active Active
- 2017-02-21 US US16/487,162 patent/US11180444B2/en active Active
- 2017-02-21 HR HRP20211412TT patent/HRP20211412T1/hr unknown
- 2017-02-21 SI SI201730887T patent/SI3598868T1/sl unknown
-
2019
- 2019-08-26 ZA ZA2019/05612A patent/ZA201905612B/en unknown
-
2021
- 2021-06-07 JP JP2021095156A patent/JP7101293B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2484085C2 (ru) * | 2007-03-06 | 2013-06-10 | Зика Текнолоджи Аг | Диальдимин, эмульсия, содержащая диальдимин, а также двухкомпонентная полиуретановая композиция и ее применение |
Non-Patent Citations (1)
| Title |
|---|
| J.LIU et al. Synthesis and antibacterial activities of para-alkoxy phenyl-β-ketoaldehyde derivatives, MED. CHEM. RES., 2013, vol. 22, no. 9, pp. 4228-4238. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021152031A (ja) | 2021-09-30 |
| US20200062697A1 (en) | 2020-02-27 |
| KR20190118609A (ko) | 2019-10-18 |
| JP7101293B2 (ja) | 2022-07-14 |
| PL3598868T3 (pl) | 2021-12-06 |
| PT3598868T (pt) | 2021-09-09 |
| WO2018154344A1 (en) | 2018-08-30 |
| HRP20211412T1 (hr) | 2021-12-10 |
| KR102296053B1 (ko) | 2021-09-01 |
| ZA201905612B (en) | 2021-09-29 |
| DK3598868T3 (da) | 2021-09-06 |
| CA3053236C (en) | 2023-12-19 |
| EP3598868A1 (en) | 2020-01-29 |
| EP3598868B1 (en) | 2021-06-09 |
| BR112019017085A2 (pt) | 2020-04-07 |
| CA3053236A1 (en) | 2018-08-30 |
| AU2017399805B2 (en) | 2020-10-01 |
| JP2020508297A (ja) | 2020-03-19 |
| AU2017399805A1 (en) | 2019-09-05 |
| US11180444B2 (en) | 2021-11-23 |
| CN110325245A (zh) | 2019-10-11 |
| SI3598868T1 (sl) | 2021-10-29 |
| AU2017399805A2 (en) | 2019-10-03 |
| ES2888948T3 (es) | 2022-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10308686B2 (en) | Gamma-AApeptides with potent and broad-spectrum antimicrobial activity | |
| CN114829374A (zh) | 结合pbp的双环肽配体 | |
| TWI595002B (zh) | （Ｒ）－２－（５－（２－（３－乙基脲基）－６－氟－７－（四氫呋喃－２－基）－１Ｈ－苯并［ｄ］咪唑－５－基）嘧啶－２－基）丙烷－２－基磷酸二氫鹽之固體形式及其鹽 | |
| RU2625305C2 (ru) | Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины | |
| JP7101293B2 (ja) | 新規ポリイミノケトアルデヒド | |
| US20220105076A1 (en) | Inhibitor for V-Atpase Activity, Antibacterial Agent, Medicine, Antibacterial Method and Screening Method | |
| CA2957691C (en) | Antibacterial sideromycins | |
| US12378328B2 (en) | Biohybrid peptidoglycan oligomers | |
| PL249237B1 (pl) | Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna | |
| CN112165936A (zh) | β-内酰胺酶抑制剂 | |
| EP4532512A2 (en) | Cilagicin compounds and methods of use thereof | |
| BR112019017085B1 (pt) | Composto poliimino cetoaldeído e preparação farmacêutica contendo-o | |
| WO2018214463A1 (zh) | 新型抗生素及其制备方法、用途、应用 | |
| ES2752040B2 (es) | Cepa bacteriana de Streptomyces Althioticus productora de desertomicinas y desertomicina producida por la misma | |
| JP2023543894A (ja) | ヘキソースリン酸とコンジュゲートされた薬物およびその製造方法と使用方法 | |
| EA050355B1 (ru) | Фармацевтическая субстанция для формирования антибактериальных лекарственных препаратов на основе 4-(3-этокси-4-гидроксибензил)-5-оксо-5,6-дигидро-4h-[1,3,4]-тиадиазин-2-(2,4-дифторфенил)карбоксамида и фармацевтическая композиция на ее основе | |
| ES2585929B1 (es) | Cepa bacteriana de pseudonocardia carboxydivorans productora de branimicinas y branimicinas producidas por la misma | |
| WO2021205372A2 (en) | Antibacterial lipopeptides, pharmaceutical composition and cosmetic composition comprising them, and uses thereof |